SBIO: Big Pharma Needs What This Fund Owns

Summary The ALPS Medical Breakthroughs ETF targets late-stage biotech firms primed for clinical catalysts and acquisition interest. SBIO's methodology requires at least one Phase II/III program and 24 months of cash, reducing dilution risk before key events. Recent acquisitions of top holdings post-August highlight SBIO's ability to capture M&A-driven upside and recycle capital into new prospects. Despite high volatility and turnover, the recent pullback offers an improved entry point for exposure to late-stage biotech upside. Solskin/DigitalVision via Getty Images Thesis The ALPS Medical Breakthroughs ETF ( SBIO ) is a passive thematic biotech ETF that tracks the S-Network Medical Breakthroughs Index. This isn't exactly a fund that rises or falls with the fortunes of established pharmaceutical This article was written by Grassroots Trading 3.24K Followers Follow As of August 2026, I'm globally ranked in the top 1.5% of investment experts and financial bloggers on TipRanks. My goal is to clarify the complexities of investment opportunities and risks for both individual and professional investors, while also helping newer investors build confidence as they learn to evaluate opportunities with a disciplined, long-term mindset, so please follow me if this is the type of research you’re looking to read. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SBIO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.